SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Atrium Therapeutics, Inc. (RNA) has a negative trailing P/E of -3.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 7.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -32.34%, forward earnings yield 13.07%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+288.7%).
- Forward P/E 7.7 — analysts expect a return to profitability with estimated EPS of $1.83 for FY2029.
- Trailing Earnings Yield -32.34% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 13.07% as earnings recover.
- Analyst consensus target $54.50 (+288.7% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 53/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RNA
Valuation Multiples
P/E (TTM)-3.1
Forward P/E7.7
PEG RatioN/A
Forward PEGN/A
P/B Ratio1.14
P/S Ratio11.55
EV/EBITDA0.7
Per Share Data
EPS (TTM)$-4.48
Forward EPS (Est.)$1.83
Book Value / Share$12.11
Revenue / Share$1.09
FCF / Share$-2.49
Yields & Fair Value
Earnings Yield-32.34%
Forward Earnings Yield13.07%
Dividend Yield0.00%
Analyst Target$54.50 (+288.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2025 |
-3.3 |
0.00 |
1.22 |
13.56 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2018 |
$-0.58 |
$379K |
$-11.93M |
-3148.8% |
| 2019 |
$-0.86 |
$2.32M |
$-32.12M |
-1385.1% |
| 2020 |
$-2.03 |
$6.79M |
$-43.98M |
-648% |
| 2021 |
$-2.83 |
$9.33M |
$-117.37M |
-1258.5% |
| 2022 |
$-3.24 |
$9.22M |
$-169.08M |
-1833% |
| 2023 |
$-2.91 |
$9.56M |
$-212.22M |
-2219.9% |
| 2024 |
$-2.89 |
$10.9M |
$-322.3M |
-2957.7% |
| 2025 |
$-4.48 |
$18.62M |
$-76.68M |
-411.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-5.04 |
$-8.81 – $-2.00 |
$21.66M |
$8.73M – $50.07M |
4 |
| 2027 |
$-4.01 |
$-4.05 – $-3.95 |
$287.52M |
$149.28M – $438.09M |
3 |
| 2028 |
$-1.82 |
$-4.48 – $1.96 |
$913.03M |
$876.21M – $949.85M |
6 |
| 2029 |
$1.83 |
$0.73 – $3.21 |
$1.61B |
$862.06M – $2.54B |
4 |
